SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-22-008541
Filing Date
2022-03-31
Accepted
2022-03-31 17:09:44
Documents
99
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 2371971
2 ex21-1.htm EX-21.1 8214
3 ex23-1.htm EX-23.1 5080
4 ex31-1.htm EX-31.1 18747
5 ex31-2.htm EX-31.2 18772
6 ex32-1.htm EX-32.1 8642
7 ex32-2.htm EX-32.2 8281
  Complete submission text file 0001493152-22-008541.txt   11687267

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE prph-20211231.xsd EX-101.SCH 72735
9 XBRL CALCULATION FILE prph-20211231_cal.xml EX-101.CAL 117260
10 XBRL DEFINITION FILE prph-20211231_def.xml EX-101.DEF 317878
11 XBRL LABEL FILE prph-20211231_lab.xml EX-101.LAB 619282
12 XBRL PRESENTATION FILE prph-20211231_pre.xml EX-101.PRE 485740
93 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 2266144
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

IRS No.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-21617 | Film No.: 22794034
SIC: 2834 Pharmaceutical Preparations